TMCnet News

Global Antibody Drug Conjugates Market By Drug (ADCETRIS, Kadcyla), Pipeline Analysis (By Phase, Mode of Action, Linker, Technology, and Indication) Outlook 2022 - Research and Markets
[February 22, 2017]

Global Antibody Drug Conjugates Market By Drug (ADCETRIS, Kadcyla), Pipeline Analysis (By Phase, Mode of Action, Linker, Technology, and Indication) Outlook 2022 - Research and Markets


Research and Markets has announced the addition of the "Global Antibody Drug Conjugates Market By Drug (ADCETRIS, Kadcyla), Pipeline Analysis (By Phase, Mode of Action, Linker, Technology, and Indication) Outlook 2022" report to their offering.

The ADC (News - Alert) market is poised to reach US$ 18.1 Billion by 2022. In this report, there is in-depth market analysis of ADCETRIS and Kadcyla.

The market potential of these ADCs is estimated considering that these are being tested in clinical trials for several cancer indications, besides the ones which have already been approved. The depicted ADCs are expected to show their complete market potential soon in the coming years.

Furthermore, in this report, we have structured the information regarding ADCs at various stages of clinical development that are under research or in collaboration, and those individually being developed by companies. The pipeline chapter provides in depth analysis of ADCs of companies as well as research organizations by clinical phase, ndications for which they are being developed, mode of action, type of linker, drugs, and technology. Additionally, the study provides all-inclusive current analysis of various ADCs in advanced as well as early stages of development. Moreover, our report places an emphasis on the major drivers and challenges, latest trends and developments, as well as strategic collaborations that can impact industry's growth.



In the end, the report enlists some of the key players in the ADC market including in-short business overview of each player along with their product and pipeline portfolios, recent developments, and comparative analysis of their strengths and weaknesses. Conclusively, the report will prove to be a complete and comprehensive source of knowledge and analysis for clients and potential investors or debut makers in this industry.

Key Topics Covered:


1. Analyst View

2. Research Methodology

3. Antibody Drug Conjugate (ADC) - An Introduction

4. ADC Market Outlook to 2022

6. Drivers and Challenges

7. Major Potential ADCs in Pipeline

8. Trends and Developments

9. Strategic Collaborations in the ADC Industry

10. Competitive Assessment

  • Agensys, Inc.
  • Bayer AG
  • Concortis Biotherapeutics
  • F. Hoffman (News - Alert)-La Roche Ltd.
  • ImmunoGen, Inc.
  • Immunomedics, Inc.
  • NBE-Therapeutics
  • Novartis AG
  • Seattle Genetics, Inc.
  • Takeda Pharmaceutical Company Limited

For more information about this report visit http://www.researchandmarkets.com/research/925h6c/global_antibody


[ Back To TMCnet.com's Homepage ]